CARDIOL THERAPEUTICS INC-A (CRDL) Stock Price, Forecast & Analysis
NASDAQ:CRDL • CA14161Y2006
CRDL Key Statistics, Chart & Performance
The current stock price of CRDL is 1.04 USD. In the past month the price increased by 2.97%. In the past year, price decreased by -13.33%.
CRDL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CRDL. When comparing the yearly performance of all stocks, CRDL is a bad performer in the overall market: 73.36% of all stocks are doing better.
CRDL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRDL. Both the profitability and financial health of CRDL have multiple concerns.
CRDL Financial Highlights
Over the last trailing twelve months CRDL reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS increased by 24.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -268.65% | ||
| ROE | -363.82% | ||
| Debt/Equity | 0.01 |
CRDL Forecast & Estimates
8 analysts have analysed CRDL and the average price target is 7.03 USD. This implies a price increase of 576.1% is expected in the next year compared to the current price of 1.04.
CRDL Ownership
CRDL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 964.817B | ||
| JNJ | JOHNSON & JOHNSON | 21.03 | 590.254B | ||
| MRK | MERCK & CO. INC. | 22.49 | 301.963B | ||
| PFE | PFIZER INC | 9.11 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.82 | 121.595B | ||
| ZTS | ZOETIS INC | 18.8 | 56.906B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.74 | 26.172B | ||
| VTRS | VIATRIS INC | 6.35 | 18.486B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.7 | 12.312B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.58 | 9.313B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRDL
Company Profile
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Company Info
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO CA
Employees: 18
Phone: 12899100850
CARDIOL THERAPEUTICS INC-A / CRDL FAQ
What does CARDIOL THERAPEUTICS INC-A do?
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario and currently employs 18 full-time employees. The company went IPO on 2018-12-20. The firm's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The firm is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
What is the stock price of CARDIOL THERAPEUTICS INC-A today?
The current stock price of CRDL is 1.04 USD.
What is the dividend status of CARDIOL THERAPEUTICS INC-A?
CRDL does not pay a dividend.
How is the ChartMill rating for CARDIOL THERAPEUTICS INC-A?
CRDL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy CRDL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRDL.
What is CARDIOL THERAPEUTICS INC-A worth?
CARDIOL THERAPEUTICS INC-A (CRDL) has a market capitalization of 116.15M USD. This makes CRDL a Micro Cap stock.